NDMC101 inhibits osteoclast production, thereby improving paw swelling and inflammatory bone destruction, a process associated with inhibition of transcription factors such as NF-κB and NFATc1, as well as multiple protein kinases, including p38, ERK, and JNK.

 

Brand: BCM

 

Target: Proteasome; NF-κB; Others

 

Signaling Pathways: NF-κB; Others; Proteases/Proteasome; Ubiquitination

 

Boiling Point: 311.1±42.0 °C at 760 mmHg

 

Flashing Point: 142.0±27.9 °C

 

pKa: 8.15±0.30(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

GHS: GHS07

 

Isomeric SMILES: C1=CC=C(C(=C1)C(=O)NC2=C(C=C(C=C2)Cl)F)O  

 

InChIKey: NUQWCDAXACRITO-UHFFFAOYSA-N  

 

InChI: InChI=1S/C13H9ClFNO2/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17/h1-7,17H,(H,16,18) 

 

Attribute
[Chem Name]	N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide
[Synonym]	NDMC101
[CAS No.]	1308631-40-4
[MDL No.]	MFCD13200880
[Formula]	C13H9ClFNO2
[Molecular]	265.67
[Form]	Solid powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag